{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:52:23Z","timestamp":1790833943461,"version":"4.1.0"},"reference-count":36,"publisher":"Walter de Gruyter GmbH","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background:<\/jats:title><jats:p>Peak gonadotropin-releasing hormone or agonist (GnRHa) stimulated luteinizing hormone (LH) testing with leuprolide acetate (LA) is commonly used to document suppression during therapy for central precocious puberty (CPP). The objective of the study was to investigate suitability of using basal LH levels to monitor GnRHa treatment and to determine optimal transition from 1-month to 3-month LA formulations via a post hoc analysis of a randomized, open-label, 6-month study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>A total of 42 children with CPP, pretreated with 7.5-, 11.25-, or 15-mg 1-month LA formulations were randomized to 11.25- or 30-mg 3-month LA. Basal LH\/peak-stimulated LH levels were measured at weeks 0, 4, 8 and 12. Positive\/negative predictive values and sensitivities\/specificities were determined for basal LH vs. LH-stimulation results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Pretreatment with any 1-month formulation for the most part did not affect continuation of suppression after transitioning to 3-month formulation (mean peak-stimulated LH levels remained &lt; 4 IU\/L). Basal LH predicted suppression escape (basal LH-level cutoff \u2265 0.6 IU\/L predicted 70% of those failing suppression). Tolerability was similar, regardless of dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Our data indicate that a basal level of &lt;0.60 IU\/L is adequate for monitoring suppression approximately two-thirds of the time. Furthermore, the effectiveness and safety of 3-month LA treatments are not influenced by previous CPP therapies.<\/jats:p><\/jats:sec>","DOI":"10.1515\/jpem-2016-0026","type":"journal-article","created":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T10:02:21Z","timestamp":1476439341000},"source":"Crossref","is-referenced-by-count":7,"title":["Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation"],"prefix":"10.1515","volume":"0","author":[{"given":"Peter A.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Luce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","reference":[{"key":"ref21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/humupd\/dmh012","article-title":"Precocious puberty and statural growth","volume":"10","year":"2004","journal-title":"Hum Reprod Update"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0022-3476(95)70254-7","article-title":"Normal ranges for immunochemiluminometric gonadotropin assays","volume":"127","year":"1995","journal-title":"J Pediatr"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-3476(95)70255-5","article-title":"Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty","volume":"127","year":"1995","journal-title":"J Pediatr"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/00008480-200008000-00020","article-title":"Management of central isosexual precocity: diagnosis, treatment, outcome","volume":"12","year":"2000","journal-title":"Curr Opin Pediatr"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1210\/jc.2013-4471","article-title":"36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty","volume":"99","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref351","volume-title":"Assessing the skeletal maturity of the hand-wrist: FELS method","year":"1988"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1210\/jc.2011-2704","article-title":"Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty","volume":"97","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"e752","DOI":"10.1542\/peds.2008-1783","article-title":"Consensus statement on the use of gonadotropin-releasing hormone analogs in children","volume":"123","year":"2009","journal-title":"Pediatrics"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1530\/EJE-08-0814","article-title":"The use of GnRH agonists in precocious puberty","volume":"159","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1687-9856-2013-20","article-title":"Random unstimulated pediatric luteinizing hormone levels are not reliable in the assessment of pubertal suppression during histrelin implant therapy","volume":"2013","year":"2013","journal-title":"Int J Pediatr Endocrinol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1530\/EJE-08-0814","article-title":"The use of GnRH agonists in precocious puberty","volume":"159","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jpeds.2012.08.038","article-title":"Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty","volume":"162","year":"2013","journal-title":"J Pediatr"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1687-9856-2013-20","article-title":"Random unstimulated pediatric luteinizing hormone levels are not reliable in the assessment of pubertal suppression during histrelin implant therapy","volume":"2013","year":"2013","journal-title":"Int J Pediatr Endocrinol"},{"key":"ref161","volume-title":"Assessing the skeletal maturity of the hand-wrist: FELS method","year":"1988"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0022-3476(05)81162-X","article-title":"Two-year results of treatment with depot leuprolide acetate for central precocious puberty","volume":"121","year":"1992","journal-title":"J Pediatr"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0889-8529(05)70108-0","article-title":"Central precocious puberty. An overview of diagnosis, treatment, and outcome","volume":"28","year":"1999","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s12098-013-1177-6","article-title":"Precocious puberty-perspectives on diagnosis and management","volume":"81","year":"2014","journal-title":"Indian J Pediatr"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1210\/jc.2006-1569","article-title":"Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children","volume":"92","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1210\/jcem.84.6.5647","article-title":"Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of decapeptyl in precocious puberty","volume":"84","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s12098-013-1177-6","article-title":"Precocious puberty-perspectives on diagnosis and management","volume":"81","year":"2014","journal-title":"Indian J Pediatr"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"e1059","DOI":"10.1542\/peds.2008-1180","article-title":"Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls","volume":"123","year":"2009","journal-title":"Pediatrics"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jpeds.2012.08.038","article-title":"Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty","volume":"162","year":"2013","journal-title":"J Pediatr"},{"key":"ref121","first-page":"3539","article-title":"Diagnostic value of fluorometric assays in the evaluation of precocious puberty","volume":"84","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/00008480-200008000-00020","article-title":"Management of central isosexual precocity: diagnosis, treatment, outcome","volume":"12","year":"2000","journal-title":"Curr Opin Pediatr"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"e1059","DOI":"10.1542\/peds.2008-1180","article-title":"Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls","volume":"123","year":"2009","journal-title":"Pediatrics"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"e752","DOI":"10.1542\/peds.2008-1783","article-title":"Consensus statement on the use of gonadotropin-releasing hormone analogs in children","volume":"123","year":"2009","journal-title":"Pediatrics"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0022-3476(95)70254-7","article-title":"Normal ranges for immunochemiluminometric gonadotropin assays","volume":"127","year":"1995","journal-title":"J Pediatr"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0889-8529(05)70108-0","article-title":"Central precocious puberty. An overview of diagnosis, treatment, and outcome","volume":"28","year":"1999","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-3476(95)70255-5","article-title":"Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty","volume":"127","year":"1995","journal-title":"J Pediatr"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1210\/jcem.84.6.5647","article-title":"Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of decapeptyl in precocious puberty","volume":"84","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/humupd\/dmh012","article-title":"Precocious puberty and statural growth","volume":"10","year":"2004","journal-title":"Hum Reprod Update"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0022-3476(05)81162-X","article-title":"Two-year results of treatment with depot leuprolide acetate for central precocious puberty","volume":"121","year":"1992","journal-title":"J Pediatr"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1210\/jc.2006-1569","article-title":"Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children","volume":"92","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref311","first-page":"3539","article-title":"Diagnostic value of fluorometric assays in the evaluation of precocious puberty","volume":"84","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1210\/jc.2013-4471","article-title":"36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty","volume":"99","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1210\/jc.2011-2704","article-title":"Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty","volume":"97","year":"2012","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jpem.ahead-of-print\/jpem-2016-0026\/jpem-2016-0026.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2016-0026\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T01:40:35Z","timestamp":1619055635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2016-0026\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,14]]},"references-count":36,"journal-issue":{"issue":"0"},"URL":"https:\/\/doi.org\/10.1515\/jpem-2016-0026","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1,14]]}}}